US-12616725-B2 - Bifidobacterium breve IDCC 4401 strain and its dead cell ID-BBR4401 having excellent acid tolerance and bile tolerance and prophylactic or therapeutic effect on dyslipidemia

US12616725B2US 12616725 B2US12616725 B2US 12616725B2US-12616725-B2

Abstract

The present invention relates to a novel Bifidobacterium breve IDCC 4401 strain (accession number: KCTC13169BP) and dead cell thereof ID-BBR4401, which are superb in acid tolerance and bile tolerance and have a preventive or therapeutic effect on dyslipidemia. Having not only an excellent effect of reducing a cholesterol level in the body but alto a very high level of acid tolerance and bile tolerance in contrast to previously known B. breve , the novel Bifidobacterium breve IDCC 4401 strain (accession number: KCTC13169BP) of the present invention well exhibits the functionality that the strain has in the digestive duct of animals (especially humans), has an excellent growth potential, and provides sustainable and effective functionality of reducing a level of cholesterol in vivo.

Inventors

Min-goo Kim
Don-Gil Lee
Tae-Yoon Kim

Assignees

ILDONG HEALTHCARE CO., LTD.

Dates

Publication Date: 20260505
Application Date: 20221230
Priority Date: 20200630

Claims (1)

1 . A method of treating dyslipidemia comprising administering to a mammalian subject in need thereof a composition comprising an effective amount of at least one of the isolated Bifidobacterium breve IDCC 4401 strain having the accession number KCTC13169BP, a culture thereof, or a heat-treated dead cell of the isolated Bifidobacterium breve IDCC 4401 strain.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of and claims priority to PCT International Patent Application Serial No. PCT/KR2021/007117, filed Jun. 8, 2021, which itself claims priority to Korean Patent Application No. 10-2020-0080588, filed Jun. 30, 2020, the disclosures of both of which are incorporated by reference herein in their entireties. REFERENCE TO SEQUENCE LISTING XML The Sequence Listing XML associated with the instant disclosure has been electronically submitted to the United States Patent and Trademark Office via the Patent Center as a 3,730 byte UTF-8-encoded XML file created on Dec. 30, 2022 and entitled “3204_24_PCT_US”. The Sequence Listing submitted via Patent Center is hereby incorporated by reference in its entirety. TECHNICAL FIELD The present invention relates to a novel Bifidobacterium breve IDCC 4401 strain (accession number: KCTC13169BP) and dead cell thereof ID-BBR4401 having excellent acid tolerance and bile tolerance and a preventive or therapeutic effect on dyslipidemia, and more particularly, to uses for prevention, improvement and treatment of dyslipidemia of the novel Bifidobacterium breve IDCC 4401 strain or dead cell thereof ID-BBR4401 and a composition for controlling intestinal functions, a probiotic composition, a feed composition and a fermented product comprising the strain as an active ingredient. BACKGROUND Dyslipidemia refers to a state in which total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides are increased, or high-density lipoprotein (HDL) cholesterol is decreased in the blood. The dyslipidemia is a broad disease name that includes all hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia, and among them, hypercholesterolemia refers to a disease in which total cholesterol and low-density lipoprotein cholesterol are high in a state in which cholesterol is increased in the blood. The hypercholesterolemia is defined when the serum cholesterol level is highest due to cholesterol metabolism disorder or excessive intake of cholesterol. Cholesterol is an essential component of the human body, but its metabolic abnormality is greatly related to the onset of adult diseases, especially arteriosclerosis. It is known that about 140 g of cholesterol is present in adults, about 1% of which is metabolized daily, and an important metabolite is bile acids. The bile acids are not only a metabolite of cholesterol, but also form micelles with cholesterol-containing lipids in the digestive tract to promote its absorption. Since the bile acids are essential for the formation of micelles, the absence of bile acids interferes with the absorption of fat-soluble substances such as lipids and vitamins. Secreted bile acids represent the enterohepatic circulation where the bile acids are absorbed from the intestinal tract, returned to the liver, and secreted back into the bile. It is known that when the bile acids are not reabsorbed but released during such circulation, the requirement of cholesterol, which is a precursor, to biosynthesize new bile acids also increases to lower cholesterol levels in vivo. In general, hypercholesterolemia is determined when the cholesterol concentration in serum (plasma) is 220 to 250 mg/dL or higher, or when the low-density lipoprotein cholesterol concentration is 160 mg/dL or higher. If the high cholesterol state continues for a long time, the cholesterol is deposited on the arterial wall to cause atherosclerosis and cause myocardial infarction or cerebral thrombosis. In addition, the cholesterol is deposited in connective tissue to cause xanthomas or easily cause cholelithiasis, including cholesterin stones. Some patients with hypercholesterolemia may use drug treatment depending on the severity of the symptoms, but statin-based drugs are the most commonly used. The statin-type drugs are HMG-CoA reductase inhibitors and have the effect of inhibiting cholesterol synthesis (Ki-Hun Han et al., Grounds for statin clinical studies, the Korean Society of Lipid and Arteriosclerosis Treatment Guidelines Committee (2010) pp. 14˜15). Statins decrease low-density lipoprotein cholesterol and triglycerides in a dose-dependent manner and partially increase high-density lipoprotein cholesterol. Side effects of these statins include indigestion, headache, fatigue, joint pain, and the like, and if there are muscle symptoms due to the risk of myopathy, a blood test is required, and because of a possibility of liver dysfunction, a liver function test is required before prescription, after 2 to 3 months of administration, and then at 1-year intervals. Accordingly, research on safer materials without side effects is being conducted, and recently, many studies on functional foods that can be combined with diet have been conducted. Accordingly, part of the effort to improve hypercholesterolemia has been attempted in the field of research using probiotics strains. Meanwhile, a dead cell of lactic acid bacteria